Home Cart Sign in  
Chemical Structure| 439081-18-2 Chemical Structure| 439081-18-2

Structure of (E/Z)-Afatinib
CAS No.: 439081-18-2

Chemical Structure| 439081-18-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Afatinib is an irreversible inhibitor of pan-ErbB inhibitor with IC50 values of 0.4nM, 0.5nM, 10nM, 14nM and 1nM for EGFR (L858R), EGFR (wt), EGFR (L858R/T790M), HER2 and ErbB4, respectively.

Synonyms: (E/Z)-BIBW 2992

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of (E/Z)-Afatinib

CAS No. :439081-18-2
Formula : C24H25ClFN5O3
M.W : 485.93
SMILES Code : O=C(NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@@H]4COCC4)C=CCN(C)C
Synonyms :
(E/Z)-BIBW 2992
MDL No. :MFCD12407405
InChI Key :ULXXDDBFHOBEHA-CWDCEQMOSA-N
Pubchem ID :10184653

Safety of (E/Z)-Afatinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of (E/Z)-Afatinib

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02145637 NSCLC Phase 1 Unknown July 2016 -
NCT01649284 - - - -
NCT03054038 Non-Small Cell Lung Carcinoma Phase 1 Recruiting March 2021 United States, California ... More >> City of Hope National Medical Center Recruiting Duarte, California, United States, 91010 Contact: Thomas Fok       tfok@coh.org    Principal Investigator: Karen Reckamp, MD          Stanford Cancer Institute Recruiting Stanford, California, United States, 94035 Contact: Jordan Preiss    650-723-1002       Principal Investigator: Sukhmani Padda, MD          United States, Tennessee Vanderbilt-Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Less <<
NCT01085136 Carcinoma, Non-Small-Cell Lung Phase 3 Completed - -
NCT00730925 Carcinoma, Non-Small-Cell Lung Phase 2 Completed - Belgium ... More >> 1200.41.32003 Boehringer Ingelheim Investigational Site Antwerpen, Belgium 1200.41.32007 Boehringer Ingelheim Investigational Site Charleroi, Belgium 1200.41.32001 Boehringer Ingelheim Investigational Site Jette, Belgium 1200.41.32011 Boehringer Ingelheim Investigational Site Leuven, Belgium 1200.41.32008 Boehringer Ingelheim Investigational Site Liège, Belgium 1200.41.32006 Boehringer Ingelheim Investigational Site Namur, Belgium Spain 1200.41.34001 Boehringer Ingelheim Investigational Site Badalona (Barcelona), Spain Less <<
NCT02491775 - Terminated(Changes in treatmen... More >>t plan affecting drug therapy choices) Less << - United States, Missouri ... More >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 Less <<
NCT00525148 - Completed - -
NCT01441596 Breast Neoplasms ... More >> Neoplasm Metastasis Less << Phase 2 Completed - -
NCT01085136 - Completed - -
NCT01679405 Metastatic Disease Phase 1 Terminated(2016/04/26) December 2016 Germany ... More >> I. Medizinische Klinik und Poliklinik der Universitätsmedizin Mainz, Germany, 55131 Less <<
NCT00525148 Carcinoma, Non-Small-Cell Lung Phase 2 Completed - -
NCT01441596 - Completed - -
NCT00727506 Glioma Phase 2 Completed - -
NCT00730925 - Completed - -
NCT01271725 Breast Neoplasms Phase 2 Completed - Hong Kong ... More >> 1200.98.85202 Boehringer Ingelheim Investigational Site Hong Kong, Hong Kong 1200.98.85201 Boehringer Ingelheim Investigational Site Shatin, Hong Kong India 1200.98.91011 Boehringer Ingelheim Investigational Site Amravati, India 1200.98.91009 Boehringer Ingelheim Investigational Site Maharashtra, India 1200.98.91010 Boehringer Ingelheim Investigational Site Maharashtra, India 1200.98.91004 Boehringer Ingelheim Investigational Site Nagpur, India 1200.98.91001 Boehringer Ingelheim Investigational Site Pune, India 1200.98.91005 Boehringer Ingelheim Investigational Site Thiruvananthapuram, India Poland 1200.98.48002 Boehringer Ingelheim Investigational Site Gdansk, Poland Russian Federation 1200.98.07014 Boehringer Ingelheim Investigational Site Kazan, Russian Federation 1200.98.07013 Boehringer Ingelheim Investigational Site Krasnodar, Russian Federation 1200.98.07004 Boehringer Ingelheim Investigational Site Moscow, Russian Federation 1200.98.07012 Boehringer Ingelheim Investigational Site Pyatigorsk, Russian Federation 1200.98.07008 Boehringer Ingelheim Investigational Site Samara, Russian Federation 1200.98.07011 Boehringer Ingelheim Investigational Site Sochi, Russian Federation 1200.98.07003 Boehringer Ingelheim Investigational Site Stavropol, Russian Federation 1200.98.07006 Boehringer Ingelheim Investigational Site Yaroslavl, Russian Federation Taiwan 1200.98.88603 Boehringer Ingelheim Investigational Site Taichung, Taiwan 1200.98.88607 Boehringer Ingelheim Investigational Site Taichung, Taiwan 1200.98.88601 Boehringer Ingelheim Investigational Site Taipei, Taiwan 1200.98.88602 Boehringer Ingelheim Investigational Site Taipei, Taiwan 1200.98.88604 Boehringer Ingelheim Investigational Site Taipei, Taiwan 1200.98.88605 Boehringer Ingelheim Investigational Site Taipei, Taiwan United Kingdom 1200.98.44009 Boehringer Ingelheim Investigational Site Barnstaple, United Kingdom 1200.98.44001 Boehringer Ingelheim Investigational Site Bournemouth, United Kingdom 1200.98.44004 Boehringer Ingelheim Investigational Site Exeter, United Kingdom 1200.98.44005 Boehringer Ingelheim Investigational Site London, United Kingdom Less <<
NCT02372006 Neuroectodermal Tumors ... More >> Rhabdomyosarcoma Less << Phase 1 Phase 2 Recruiting August 15, 2019 -
NCT01396265 Healthy Phase 1 Completed - Germany ... More >> 1200.152.1 Boehringer Ingelheim Investigational Site Biberach, Germany Less <<
NCT01396265 - Completed - -
NCT00727506 - Completed - -
NCT01152437 Colorectal Neoplasms Phase 2 Completed - United Kingdom ... More >> 1200.74.44001 Boehringer Ingelheim Investigational Site Bournemouth, United Kingdom 1200.74.44005 Boehringer Ingelheim Investigational Site Bristol, United Kingdom 1200.74.44006 Boehringer Ingelheim Investigational Site Cambridge, United Kingdom 1200.74.44003 Boehringer Ingelheim Investigational Site Glasgow, United Kingdom 1200.74.44009 Boehringer Ingelheim Investigational Site London, United Kingdom 1200.74.44012 Boehringer Ingelheim Investigational Site Manchester, United Kingdom 1200.74.44007 Boehringer Ingelheim Investigational Site Northwood, United Kingdom 1200.74.44013 Boehringer Ingelheim Investigational Site Nottingham, United Kingdom 1200.74.44011 Boehringer Ingelheim Investigational Site Poole, United Kingdom 1200.74.44010 Boehringer Ingelheim Investigational Site Sheffield, United Kingdom 1200.74.44008 Boehringer Ingelheim Investigational Site Southampton, United Kingdom 1200.74.44004 Boehringer Ingelheim Investigational Site Sutton, Surrey, United Kingdom 1200.74.44002 Boehringer Ingelheim Investigational Site Truro, United Kingdom Less <<
NCT01152437 - Completed - -
NCT01426958 - Completed - -
NCT01298063 Liver Diseases ... More >> Healthy Less << Phase 1 Completed - Germany ... More >> 1200.86.1 Boehringer Ingelheim Investigational Site Kiel, Germany Less <<
NCT02541903 Penile Squamous Cell Carcinoma... More >> (PSCC) Less << Phase 2 Recruiting October 2019 United States, Alabama ... More >> University of Alabama at Birmingham Recruiting Birmingham, Alabama, United States, 35294 Contact: Pam Dixon, RN, BSN, OCN    205-975-9875    pamdixon@uab.edu    Principal Investigator: Lisle Nabell, MD          United States, California University of Southern California Recruiting Los Angeles, California, United States, 90033 Contact: Tanya Dorff, MD    323-865-3900    dorff@usc.edu    United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Cherie Perez    713-563-1602    GUClinicalTrials@mdanderson.org    Principal Investigator: John Araujo, MD Less <<
NCT01298063 - Completed - -
NCT00796549 Carcinoma, Non-Small-Cell Lung Phase 2 Completed - Italy ... More >> 1200.40.39011 Boehringer Ingelheim Investigational Site Arezzo, Italy 1200.40.39007 Boehringer Ingelheim Investigational Site Aviano (PN), Italy 1200.40.39013 Boehringer Ingelheim Investigational Site Faenza (RA), Italy 1200.40.39003 Boehringer Ingelheim Investigational Site Genova, Italy 1200.40.39010 Boehringer Ingelheim Investigational Site Livorno, Italy 1200.40.39012 Boehringer Ingelheim Investigational Site Lugo (RA), Italy 1200.40.39008 Boehringer Ingelheim Investigational Site Modena, Italy 1200.40.39005 Boehringer Ingelheim Investigational Site Monza (MI), Italy 1200.40.39006 Boehringer Ingelheim Investigational Site Padova, Italy 1200.40.39002 Boehringer Ingelheim Investigational Site Perugia, Italy 1200.40.39004 Boehringer Ingelheim Investigational Site Prato, Italy 1200.40.39009 Boehringer Ingelheim Investigational Site Ravenna, Italy 1200.40.39001 Boehringer Ingelheim Investigational Site Rozzano (MI), Italy Less <<
NCT00431067 - Completed - -
NCT00796549 - Completed - -
NCT00950742 Breast Neoplasms Phase 1 Completed - United Kingdom ... More >> 1200.68.44001 Boehringer Ingelheim Investigational Site Brighton, United Kingdom 1200.68.44003 Boehringer Ingelheim Investigational Site Cambridge, United Kingdom 1200.68.44005 Boehringer Ingelheim Investigational Site Guildford, United Kingdom 1200.68.44004 Boehringer Ingelheim Investigational Site Newcastle upon Tyne, United Kingdom 1200.68.44002 Boehringer Ingelheim Investigational Site Truro, United Kingdom Less <<
NCT01426958 Healthy Phase 1 Completed - Germany ... More >> 1200.151.1 Boehringer Ingelheim Investigational Site Biberach, Germany Less <<
NCT00431067 Breast Neoplasms Phase 2 Completed - United States, Arizona ... More >> 1200.11.3 Boehringer Ingelheim Investigational Site Scottsdale, Arizona, United States United States, California 1200.11.7 Boehringer Ingelheim Investigational Site Encinitas, California, United States 1200.11.4 Boehringer Ingelheim Investigational Site Santa Monica, California, United States United States, Florida 1200.11.2 Boehringer Ingelheim Investigational Site Tampa, Florida, United States United States, Massachusetts 1200.11.1 Boehringer Ingelheim Investigational Site Boston, Massachusetts, United States United States, North Carolina 1200.11.5 Boehringer Ingelheim Investigational Site Chapel Hill, North Carolina, United States United Kingdom 1200.11.4401 Boehringer Ingelheim Investigational Site Bournemouth, United Kingdom 1200.11.4402 Boehringer Ingelheim Investigational Site Crownhill, Plymouth, United Kingdom 1200.11.4406 Boehringer Ingelheim Investigational Site Guildford, United Kingdom 1200.11.4405 Boehringer Ingelheim Investigational Site London, United Kingdom 1200.11.4404 Boehringer Ingelheim Investigational Site Poole, United Kingdom 1200.11.4403 Boehringer Ingelheim Investigational Site Truro, United Kingdom Less <<
NCT00950742 - Completed - -
NCT00875433 Neoplasms Phase 2 Completed - United Kingdom ... More >> 1200.24.4403 Boehringer Ingelheim Investigational Site Guildford, United Kingdom 1200.24.4402 Boehringer Ingelheim Investigational Site London, United Kingdom 1200.24.4404 Boehringer Ingelheim Investigational Site London, United Kingdom 1200.24.4401 Boehringer Ingelheim Investigational Site Sutton, United Kingdom Less <<
NCT00875433 - Completed - -
NCT01931306 - - - Korea, Republic of ... More >> The Catholic University of Korea, Bucheon St.Mary's Hospital Bucheon, Korea, Republic of, 14647 Gachon University Gil Medical Center Incheon, Korea, Republic of, 405-760 Chonnam National University Hwasun Hospital Jeonnam, Korea, Republic of, 519-763 Gyeongsang National University Hospital Jinju, Korea, Republic of, 660-702 The Catholic University of Korea, Seoul St.Mary's Hospital Seoul, Korea, Republic of, 06591 Severance Hospital Seoul, Korea, Republic of, 120-752 Samsung Medical Center Seoul, Korea, Republic of, 135-710 SMG-SNU Boramae Medical Center Seoul, Korea, Republic of, 156-707 Less <<
NCT00998296 Neoplasms Phase 1 Completed - France ... More >> 1239.14.3301A Boehringer Ingelheim Investigational Site Villejuif Cedex, France Less <<
NCT01251653 - Completed - France ... More >> 1200.93.33002 Boehringer Ingelheim Investigational Site Dijon, France 1200.93.33001 Boehringer Ingelheim Investigational Site Saint-Herblain cedex, France 1200.93.33003 Boehringer Ingelheim Investigational Site Toulouse, France Less <<
NCT02506517 Solid Tumors Phase 2 Recruiting December 2018 Canada, Ontario ... More >> Princess Margaret Cancer Centre Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Albiruni Razak, M.D.    416-586-4800 ext 3883       Principal Investigator: Albiruni Razak, M.D. Less <<
NCT01647711 Carcinoma, Non-Small-Cell Lung Phase 1 Completed - United States, Colorado ... More >> Boehringer Ingelheim Investigational Site Aurora, Colorado, United States United States, Massachusetts Boehringer Ingelheim Investigational Site Boston, Massachusetts, United States Less <<
NCT01649271 Breast Neoplasms ... More >> Stomach Neoplasms Less << Phase 1 Completed - France ... More >> CTR Georges-François Leclerc Dijon, France, 21079 CTR René Gauducheau, Onco, St Herblain Saint Herblain Cedex, France, 44805 INS Claudius Regaud Toulouse, France, 31059 Less <<
NCT00998296 - Completed - -
NCT02597946 Carcinoma, Non-Small-Cell Lung Phase 2 Completed - China ... More >> Hunan Province Tumor Hospital Changsha, China, 410013 First Affiliated Hospital of Guangzhou Medical University Guangzhou, China, 510120 Zhejiang Cancer Hospital Hangzhou, China, 310022 The Second Affiliated Hospital to Nanchang University Nanchang, China, 330006 First Hospital Affiliated with Nanjing Medical University Nanjing, China, 210029 Zhongshan Hospital Fudan University Shanghai, China, 200032 Shanghai Pulmonary Hospital Shanghai, China, 200433 Henan Cancer Hospital Zhengzhou, China, 450008 Malaysia University Malaya Medical Centre Kuala Lumpur, Malaysia, 59100 Less <<
NCT01647711 - Completed - -
NCT03157089 Carcinoma, Non-Small-Cell Lung Phase 2 Recruiting October 9, 2020 United States, California ... More >> University of California Davis Recruiting Sacramento, California, United States, 95817 Contact: Jonathan Riess    +001 (916) 734-3772    jwriess@ucdavis.edu    United States, District of Columbia Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital Recruiting Washington, District of Columbia, United States, 20016 Contact: Benjamin Levy    +001 (202) 660-6500    blevy11@jhmi.edu    United States, Florida Florida Hospital Recruiting Orlando, Florida, United States, 32804 Contact: Tarek Mekhail    +001 (407) 303-3235    tarek.mekhail.md@flhosp.org    United States, Kentucky Baptist Health Medical Group Recruiting Lexington, Kentucky, United States, 40503 Contact: Firas Badin    +001 (859) 276-0414    firas.badin@bhsi.com    United States, Nevada Comprehensive Cancer Centers of Nevada Recruiting Las Vegas, Nevada, United States, 89128 Contact: Brian Vicuna    +001 (702) 952-2140    brian.vicuna@usoncology.com    United States, New York Weill Cornell Medical College Recruiting New York, New York, United States, 10021 Contact: Ronald Scheff    +001 (646) 962-2066    rjs2002@med.cornell.edu    United States, Washington Cancer Care Northwest Centers, PS Recruiting Spokane Valley, Washington, United States, 99216 Contact: Srivalli Gopaluni    +001 (509) 228-1000    srivalli.gopaluni@ccnw.net    France HOP Côte de Nacre Recruiting Caen, France, 14033 Contact: Jeannick Madelaine    +33 (0)2 31 06 46 76    Madelaine-j@chu-caen.fr    HOP Le Mans Recruiting Le Mans, France, 72037 Contact: Olivier Molinier    +33 (0)2 43 43 24 50    omolinier@ch-lemans.fr    HOP Nord Recruiting Marseille, France, 13015 Contact: Fabrice Barlesi    +33 (0)4 91 38 56 28    fabrice.barlesi@ap-hm.fr    HOP Nord Laënnec Recruiting Nantes, France, 44093 Contact: Jaafar Bennouna    +33 (0)2 40 67 99 93    Jaafar.Bennouna@univ-nantes.fr    HOP Sainte Musse Recruiting Toulon, France, 83100 Contact: Clarisse Audigier-Valette    +33 (0)4 94 14 56 10    clarisse.audigier-valette@ch-toulon.fr    Korea, Republic of Severance Hospital Recruiting Seoul, Korea, Republic of, 03722 Contact: Hye Ryun Kim    82 2 2228 8125    nobelg@yuhs.ac    Asan Medical Center Recruiting Seoul, Korea, Republic of, 05505 Contact: Sang-We Kim    82 2 3010 3215    swkim@amc.seoul.kr    Spain Hospital Vall d'Hebron Recruiting Barcelona, Spain, 08035 Contact: Enriqueta Felip    +34932746077    efelip@vhio.net    Complejo Hospitalario Universitario Insular - Materno Infantil Recruiting Las Palmas de Gran Canaria, Spain, 35016 Contact: Delvys Rodríguez Abreu    +34928441738    drodabr@gobiernodecanarias.org    Hospital Universitario 12 de Octubre Recruiting Madrid, Spain, 28041 Contact: Luis Paz-Ares Rodríguez    +34913908349    lpazaresr@seom.org    Hospital Clínico Universitario Lozano Blesa Recruiting Zaragoza, Spain, 50009 Contact: Dolores Isla    +34976765746    lola.isla@gmail.com    Turkey Hacettepe Universitesi Tip Fakultesi, Onkoloji ABD Active, not recruiting Ankara, Turkey, 06230 Istanbul Universitesi Cerrahpasa Tip Fakultesi Completed Istanbul, Turkey, 34098 Less <<
NCT01251653 - Completed - -
NCT02768337 Lung Cancer B... More >>reast Cancer Brain Cancer Advanced Breast Cancer Advanced Lung Cancer Less << Phase 1 Phase 2 Recruiting December 2021 United Kingdom ... More >> Cambridge University Hospitals NHS Foundation Trust Recruiting Cambridge, England, United Kingdom, CB2 2QQ University Hospitals Birmingham NHS Foundation Trust Recruiting Birmingham, United Kingdom The Beatson West of Scotland Cancer Centre Recruiting Glasgow, United Kingdom Clatterbridge Cancer Centre Recruiting Liverpool, United Kingdom The Christie NHS Foundation Trust Recruiting Manchester, United Kingdom Oxford University Hospitals NHS Foundation Trust Recruiting Oxford, United Kingdom Less <<
NCT00716417 Neoplasms Phase 1 Completed - Belgium ... More >> 1200.37.3202 Boehringer Ingelheim Investigational Site Bruxelles, Belgium 1200.37.3201 Boehringer Ingelheim Investigational Site Edegem, Belgium 1200.37.3203 Boehringer Ingelheim Investigational Site Gent, Belgium Less <<
NCT01649271 - Completed - -
NCT00716417 - Completed - -
NCT01156545 Non-small Cell Lung Cancer Phase 2 Active, not recruiting December 2019 Korea, Republic of ... More >> National Cancer Center Goyang-si, Gyeonggi-do, Korea, Republic of, 410-769 Less <<
NCT01732640 Squamous Cell Carcinoma of the... More >> Head and Neck Less << Phase 1 Phase 2 Terminated(Slow accrual and hi... More >>gh levels of toxicity lead to early termination.) Less << - United States, Maryland ... More >> Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States, 21287 United States, Tennessee Vanderbilt Ingram Cancer Center Nashville, Tennessee, United States, 37232 Less <<
NCT03695510 Head and Neck Neoplasms Phase 2 Not yet recruiting April 2021 Taiwan ... More >> National Taiwan University Hospital Not yet recruiting Taipei, Taiwan, 100 Contact: Ruey-Long Hong, MD PhD    +886-2-23123456    rlhong@ntu.edu.tw Less <<
NCT01523587 Carcinoma, Non-Small-Cell Lung Phase 3 Completed - -
NCT01732640 - Terminated(Slow accrual and hi... More >>gh levels of toxicity lead to early termination.) Less << - -
NCT01932229 NSCLC Phase 2 Unknown - Israel ... More >> Sheba Medical Center Recruiting Ramat Gat, Israel, 52621 Contact: Dina Vornstein       Diana.Vorenshtein@sheba.health.gov.il    Principal Investigator: Jair Bar, MD-PhD Less <<
NCT01836341 Non-small Cell Lung Cancer Phase 1 Withdrawn April 2015 -
NCT02020577 Neoplasms Phase 1 Completed - France ... More >> 1200.122.33001 Boehringer Ingelheim Investigational Site Villejuif Cedex, France Spain 1200.122.34001 Boehringer Ingelheim Investigational Site Madrid, Spain Less <<
NCT01003899 Carcinoma, Non-Small-Cell Lung Phase 2 Completed - Korea, Republic of ... More >> 1200.72.8201 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1200.72.8202 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1200.72.8203 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of Less <<
NCT03652233 Recurrent Squamous Cell Carcin... More >>oma of the Head or Neck Platinum- and Cetuximab-Refractory Squamous Cell Carcinoma of the Head or Neck Metastatic Squamous Cell Carcinoma of the Head or Neck Squamous Cell Carcinoma Less << Phase 1 Not yet recruiting October 2022 United States, Tennessee ... More >> Vanderbilt-Ingram Cancer Center Not yet recruiting Nashville, Tennessee, United States, 37232 Contact: Clinical Trials Information Program    800-811-8480    cip@vanderbilt.edu    Principal Investigator: Mike Gibson, MD, PhD Less <<
NCT01003899 - Completed - -
NCT01919879 Metastatic Colorectal Cancer Phase 2 Completed - France ... More >> Institute de Cancérologie de la Loire Nantes, France, 44805 Less <<
NCT02216617 HNSCC Phase 1 Completed - France ... More >> ICM Val d'Aurelle, Montpellier Montpellier, France, 34298 Less <<
NCT01861223 NSCLC Phase 1 Phase 2 Unknown May 2016 Korea, Republic of ... More >> Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: Myung-Ju Ahn          Sub-Investigator: Jong-Mu Sun Less <<
NCT02183883 Non-small Cell Lung Cancer Phase 2 Recruiting November 2023 United Kingdom ... More >> Aberdeen Royal Infirmary (NHS Grampian) Recruiting Aberdeen, United Kingdom Principal Investigator: Gillian Price          Heart of England NHS Foundation Trust Recruiting Birmingham, United Kingdom Principal Investigator: Shobhit Baijal          Beatson West of Scotland Cancer Centre (NHS Greater Glasgow & Clyde) Recruiting Glasgow, United Kingdom Principal Investigator: Nicola Steele          Barnet and Chase Farm Hospitals (Royal Free London NHS Foundation Trust) Recruiting London Borough Of Barnet, United Kingdom Principal Investigator: Tanya Ahmad          University College London Hospitals NHS Foundation Trust Recruiting London, United Kingdom, NW1 2BU Principal Investigator: Martin Forster          Cr Uk & Ucl Ctc Active, not recruiting London, United Kingdom, W1T 4TJ The Christie NHS Foundation Trust Recruiting Manchester, United Kingdom Principal Investigator: Matthew Krebs Less <<
NCT02020577 - Completed - -
NCT00748709 - Terminated - -
NCT02780687 Urologic Neoplasms Phase 2 Recruiting March 30, 2020 France ... More >> INS Bergonié Recruiting Bordeaux, France, 33076 CTR Léon Bérard Recruiting Lyon, France, 69373 INS Cancérologie du Gard Recruiting Nîmes, France, 30029 HOP Saint-Louis Recruiting Paris, France, 75010 HOP Cochin Recruiting Paris, France, 75014 HOP Européen G. Pompidou Recruiting Paris, France, 75015 HOP Foch Recruiting Suresnes, France, 92150 INS Claudius Regaud Recruiting Toulouse, France, 31059 INS Gustave Roussy Recruiting Villejuif, France, 94805 Italy Ospedale San Donato di Arezzo Recruiting Arezzo, Italy, 52100 A.O. San Camillo Forlanini Recruiting Roma, Italy, 00152 Spain Hospital Germans Trias i Pujol Recruiting Badalona, Spain, 08916 Hospital del Mar Recruiting Barcelona, Spain, 08003 Hospital Santa Creu i Sant Pau Recruiting Barcelona, Spain, 08025 Hospital Clínic de Barcelona Recruiting Barcelona, Spain, 08036 Hospital Vall d'Hebron Recruiting Barcelona, Spain, 08038 Hospital Universitario de Elche Recruiting Elche, Spain, 03202 Hospital Universitari de Girona Doctor Josep Trueta Recruiting Girona, Spain, 17007 Hospital Duran i Reynals Recruiting L'Hospitalet de Llobregat, Spain, 08908 Hospital Universitario Lucus Augusti Recruiting Lugo, Spain, 27003 Hospital Ramón y Cajal Recruiting Madrid, Spain, 28034 Hospital Clínico San Carlos Recruiting Madrid, Spain, 28040 Hospital Universitario 12 de Octubre Recruiting Madrid, Spain, 28041 Hospital La Paz Recruiting Madrid, Spain, 28046 CIO Clara Campal Recruiting Madrid, Spain, 28050 Hospital Son Espases Recruiting Palma de Mallorca, Spain, 07010 CS Parc Taulí Recruiting Sabadell, Spain, 08208 Hospital Virgen Macarena Recruiting Sevilla, Spain, 41009 Hospital Virgen del Rocío Recruiting Sevilla, Spain, 41013 Instituto Valenciano de Oncología Recruiting Valencia, Spain, 46009 Less <<
NCT01523587 - Completed - -
NCT01325428 - Completed - -
NCT01553942 Lung Cancer Phase 2 Recruiting December 2020 United States, Massachusetts ... More >> Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Geoffrey Oxnard, MD    617-632-6049    goxnard@partners.org    Principal Investigator: Geoffrey Oxnard, MD          Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02215 Contact: Lecia V Sequist, MD MPH    617-724-4000    lvsequist@partners.org    Principal Investigator: Lecia V Sequist, MD MPH Less <<
NCT02438722 Recurrent Non-Small Cell Lung ... More >>Carcinoma Stage IV Non-Small Cell Lung Cancer Less << Phase 2 Phase 3 Active, not recruiting February 2022 -
NCT02450656 Colorectal Neoplasms ... More >> Gastrointestinal Neoplasms Pancreatic Neoplasms Carcinoma, Non-Small-Cell Lung Less << Phase 1 Phase 2 Recruiting December 2019 Netherlands ... More >> UMC St. Radboud Nijmegen Recruiting Nijmegen, Gelderland, Netherlands, 6525GA Contact: Carla ML van Herpen, MD, PhD    +31243610353    Carla.vanHerpen@radboudumc.nl    Principal Investigator: Carla ML van Herpen, MD, PhD          Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Recruiting Amsterdam, Netherlands, 1066CX Contact: F Opdam, MD, PhD          Principal Investigator: F Opdam, MD, PhD Less <<
NCT00748709 Neoplasms Phase 2 Terminated - United States, California ... More >> 1200.26.3 Boehringer Ingelheim Investigational Site Los Angeles, California, United States United States, Colorado 1200.26.11 Boehringer Ingelheim Investigational Site Denver, Colorado, United States United States, Indiana 1200.26.9 Boehringer Ingelheim Investigational Site Indianapolis, Indiana, United States United States, Massachusetts 1200.26.1 Boehringer Ingelheim Investigational Site Boston, Massachusetts, United States United States, Nevada 1200.26.13 Boehringer Ingelheim Investigational Site Las Vegas, Nevada, United States United States, New York 1200.26.4 Boehringer Ingelheim Investigational Site Albany, New York, United States 1200.26.2 Boehringer Ingelheim Investigational Site New York, New York, United States United States, Ohio 1200.26.7 Boehringer Ingelheim Investigational Site Kettering, Ohio, United States United States, Texas 1200.26.12 Boehringer Ingelheim Investigational Site Dallas, Texas, United States 1200.26.8 Boehringer Ingelheim Investigational Site Tyler, Texas, United States United States, Virginia 1200.26.6 Boehringer Ingelheim Investigational Site Norfolk, Virginia, United States United States, Washington 1200.26.10 Boehringer Ingelheim Investigational Site Vancouver, Washington, United States Taiwan 1200.26.88603 Boehringer Ingelheim Investigational Site Tainan, Taiwan 1200.26.88601 Boehringer Ingelheim Investigational Site Taipei, Taiwan 1200.26.88602 Boehringer Ingelheim Investigational Site Tao-Yuan, Taiwan Less <<
NCT01074177 Non-small Cell Lung Cancer ... More >> EGFR Mutations Less << Not Applicable Completed - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Less <<
NCT01074177 - Completed - -
NCT01325428 Breast Neoplasms Phase 2 Completed - United States, California ... More >> 1200.89.10001 Boehringer Ingelheim Investigational Site Los Angeles, California, United States United States, North Carolina 1200.89.10005 Boehringer Ingelheim Investigational Site Durham, North Carolina, United States Australia, Victoria 1200.89.61002 Boehringer Ingelheim Investigational Site East Bentleigh, Victoria, Australia Australia, Western Australia 1200.89.61003 Boehringer Ingelheim Investigational Site Perth, Western Australia, Australia Hong Kong 1200.89.85201 Boehringer Ingelheim Investigational Site Hong Kong, Hong Kong Korea, Republic of 1200.89.82001 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1200.89.82002 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of Thailand 1200.89.66002 Boehringer Ingelheim Investigational Site Bangkok, Thailand 1200.89.66004 Boehringer Ingelheim Investigational Site Bangkok, Thailand 1200.89.66003 Boehringer Ingelheim Investigational Site Chiangmai, Thailand 1200.89.66001 Boehringer Ingelheim Investigational Site Hat-Yai, Songkhla, Thailand Tunisia 1200.89.21601 Boehringer Ingelheim Investigational Site Ariana, Tunisia 1200.89.21602 Boehringer Ingelheim Investigational Site Sousse, Tunisia United Kingdom 1200.89.44002 Boehringer Ingelheim Investigational Site Bournemouth, United Kingdom 1200.89.44001 Boehringer Ingelheim Investigational Site London, United Kingdom 1200.89.44003 Boehringer Ingelheim Investigational Site London, United Kingdom Less <<
NCT01214616 Neoplasms Phase 1 Completed - Japan ... More >> 1200.84.003 Boehringer Ingelheim Investigational Site Chuo-ku, Osaka, Osaka, Japan 1200.84.004 Boehringer Ingelheim Investigational Site Kashiwa, Chiba, Japan 1200.84.001 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1200.84.002 Boehringer Ingelheim Investigational Site Sakyo-ku, Kyoto, Kyoto, Japan Less <<
NCT02716311 Non Small Cell Lung Cancer Phase 2 Recruiting January 2020 France ... More >> Centre Hospitalier du Pays d'Aix Not yet recruiting Aix-en-Provence, France Contact: Stéphanie MARTINEZ       contact@ifct.fr    Clinique de L'Europe Not yet recruiting Amiens, France Contact: Olivier CARRE, Dr          Angers - CHU Recruiting Angers, France Contact: José Hureaux, Dr          Principal Investigator: José Hureaux, Dr          Annecy - CH Recruiting Annecy, France, 74374 Contact: Chantal DECROISETTE, Dr          Bordeaux - Institut Bergonié Not yet recruiting Bordeaux, France Contact: Sylvestre LE MOULEC, Dr       contact@ifct.fr    Principal Investigator: LE MOULEC Sylvestre, Dr          Bordeaux - Polyclinique Nord Recruiting Bordeaux, France Contact: Nadine DOHOLLOU, Dr       contact@ifct.fr    Principal Investigator: Nadine DOHOLLOU, Dr          Boulogne - Ambroise Paré Recruiting Boulogne-Billancourt, France Contact: Etienne GIROUX-LEPRIEUR, MD          Principal Investigator: Etienne GIROUX-LEPRIEUR, MD          Clermont-Ferrand - CHU Not yet recruiting Clermont-Ferrand, France Contact: Patrick MERLE, MD          Principal Investigator: Patrick MERLE, MD          CH Recruiting Colmar, France Contact: Lionel MOREAU       contact@ifct.fr    CHRU Grenoble Recruiting Grenoble, France Contact: Denis MORO-SIBILOT       contact@ifct.fr    Centre Hospitalier - Pneumologie Recruiting Le Mans, France, 72000 Contact: Olivier Molinier, Dr          CHRU de Lille Recruiting Lille, France Contact: Alexis CORTOT, Pr       contact@ifct.fr    Lille - Polyclinique de la Louvière Not yet recruiting Lille, France Contact: Benjamin HURET, Dr       contact@ifct.fr    Principal Investigator: Benjamin HURET, Dr          Lyon - Hôpital Privé Jean Mermoz Not yet recruiting Lyon, France Contact: Pierre Bombaron, MD       contact@ifct.fr    Principal Investigator: Pierre BOMBARON, MD          Institut Paoli Calmette Recruiting Marseille, France Contact: Anne MADROSZYK, Dr          Montpellier - GCS Centre de Cancérologie du Grand Montpellier Not yet recruiting Montpellier, France Contact: Catherine Becht, Dr          Principal Investigator: Catherine Becht, Dr          CH de Mulhouse Recruiting Mulhouse, France Contact: Didier DEBIEUVRE       contact@ifct.fr    Nantes - ICO René Gauducheau Recruiting Nantes, France Contact: Judith RAIMBOURG, Dr       contact@ifct.fr    Principal Investigator: Judith RAIMBOURG, Dr          Nevers - CH Not yet recruiting Nevers, France, 58033 Contact: Dominique Herman, Dr          Centre Antoine Lacassagne Recruiting Nice, France Contact: Josiane OTTO, MD       contact@ifct.fr    Orléans - Hôpital de la Source Recruiting Orléans, France Contact: Hugues MOREL, Dr       contact@ifct.fr    Principal Investigator: Hugues MOREL, Dr          AP-HP Hopital Tenon - Pneumologie Recruiting Paris, France, 75020 Contact: Jacques Cadranel, Pr    +33.1.56.01.65.31    contact@ifct.fr    Principal Investigator: Jacques Cadranel, pr          Paris - APHP Bichat Not yet recruiting Paris, France Contact: Valérie Gounant, Dr       contact@ifct.fr    Principal Investigator: Valérie Gounant, Dr          Paris - APHP Saint-Louis Recruiting Paris, France Contact: Ludovic DOUCET, MD       contact@ifct.fr    Principal Investigator: Ludovic DOUCET, MD          Pau - CH Recruiting Pau, France, 64046 Contact: Aldo RENAULT, Dr       contact@ifct.fr    Pontoise - CH Not yet recruiting Pontoise, France Contact: Cécile DURAND-MATRINGE, MD       contact@ifct.fr    Principal Investigator: Cécile DURAND-MATRINGE, MD          Centre Hospitalier Recruiting Saint-Quentin, France Contact: Isabelle RAULT, MD       contact@ifct.fr    Nouvel Hopital Civil - Pneumologie Recruiting Strasbourg, France, 63000 Contact: Charlotte Leduc, Dr          Principal Investigator: Charlotte Leduc, Dr          Centre Hospitalier Intercommunal Recruiting Toulon, France Contact: Clarisse AUDIGIER-VALETTE, Dr          HIA Saint Anne Recruiting Toulon, France Contact: Henri BERARD, Dr       contact@ifct.fr    Tours - CHU Not yet recruiting Tours, France, 37000 Contact: Eric Pichon, Dr       contact@ifct.fr    CH de Villefranche - Pneumologie Recruiting Villefranche, France Contact: Luc ODIER       contact@ifct.fr    Principal Investigator: Luc ODIER          Villeneuve d'Ascq - Hôpital Privé Not yet recruiting Villeneuve-d'Ascq, France Contact: Benjamin HURET, MD          Principal Investigator: Benjamin HURET, MD Less <<
NCT01214616 - Completed - -
NCT03370770 - Completed - Austria ... More >> Otto-Wagner Hospital Vienna, Austria, 1140 Less <<
NCT02191891 Carcinoma, Non-Small-Cell Lung Phase 1 Completed - Japan ... More >> National Hospital Organization Kyushu Cancer Center Fukuoka, Fukuoka, Japan, 811-1395 Korea, Republic of Chungbuk National University Hospital Cheongju, Korea, Republic of, 361-771 Severance Hospital, Yonsei University Health System Seoul, Korea, Republic of, 120-752 Samsung Medical Center Seoul, Korea, Republic of, 135-710 Asan Medical Center Seoul, Korea, Republic of, 138-736 Singapore National Cancer Centre Singapore, Singapore, 169610 Taiwan Chang Gung Memorial Hospital Chiayi Chiayi, Taiwan, 613 Kaohsiung Chang Gung Memorial Hospital Kaohsiung, Taiwan, 83301 NCKUH Tainan, Taiwan, 704 National Taiwan University Hospital Taipei, Taiwan, 100 Less <<
NCT02470065 Non Small Cell Lung Cancer Phase 2 Suspended(Study never started) January 2021 -
NCT02979977 Squamous Cell Cancers of the H... More >>ead and Neck Less << Phase 2 Recruiting January 2020 United States, Connecticut ... More >> Yale Cancer Center Recruiting New Haven, Connecticut, United States, 06520-8028 Contact: Clinical Trials Office    203-785-5702       Principal Investigator: Aarti Bhatia, MD          United States, Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital Not yet recruiting Baltimore, Maryland, United States, 21287 Contact: Hyunseok Kang, MD, MPH          United States, Pennsylvania Fox Chase Cancer Center Not yet recruiting Philadelphia, Pennsylvania, United States, 19111 Contact: Jessica Bauman, MD Less <<
NCT02451553 Advanced Malignant Solid Neopl... More >>asm Bile Duct Carcinoma Recurrent Malignant Solid Neoplasm Recurrent Pancreatic Carcinoma Stage III Pancreatic Cancer AJCC v6 and v7 Stage IVA Pancreatic Cancer Stage IVB Pancreatic Cancer Less << Phase 1 Recruiting - United States, Indiana ... More >> Indiana University/Melvin and Bren Simon Cancer Center Recruiting Indianapolis, Indiana, United States, 46202 Contact: Sandra Wilson    317-274-3512    slhooper@iu.edu    Principal Investigator: Safi Shahda          United States, Washington Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Elena G. Chiorean    206-288-6248    gchiorea@uw.edu    Principal Investigator: Elena G. Chiorean Less <<
NCT02876081 SMALL CELL LUNG CARCINOMA Phase 2 Withdrawn(medical decision) December 2018 France ... More >> Groupe Hospitalier Paris Saint Joseph Paris, Ile-de-France, France, 75014 Less <<
NCT01480141 Lung Cancer Phase 2 Withdrawn(PI left MUSC, no pat... More >>ient enrollments) Less << - United States, South Carolina ... More >> Medical University of South Carolina Charleston, South Carolina, United States, 29425 Less <<
NCT02975141 Metastatic Pancreatic Cancer Phase 1 Active, not recruiting June 2019 Germany ... More >> Ludwig-Maximilians - University of Munich Munich, Germany, 81377 Less <<
NCT01721525 Head and Neck Cancer ... More >> Squamous Cell Cancer Less << Phase 1 Completed - United States, New Jersey ... More >> Memorial Sloan Kettering Cancer Center at Basking Ridge Basking Ridge, New Jersey, United States, 07939 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT01814553 Carcinoma, Non-Small-Cell Lung Phase 3 Completed - United States, California ... More >> 1200.167.01009 Boehringer Ingelheim Investigational Site Santa Rosa, California, United States United States, Florida 1200.167.01020 Boehringer Ingelheim Investigational Site Orlando, Florida, United States 1200.167.01018 Boehringer Ingelheim Investigational Site Port St. Lucie, Florida, United States 1200.167.01012 Boehringer Ingelheim Investigational Site St. Petersburg, Florida, United States United States, Illinois 1200.167.01007 Boehringer Ingelheim Investigational Site Skokie, Illinois, United States 1200.167.01008 Boehringer Ingelheim Investigational Site Skokie, Illinois, United States United States, New Jersey 1200.167.01001 Boehringer Ingelheim Investigational Site Morristown, New Jersey, United States United States, Oregon 1200.167.01014 Boehringer Ingelheim Investigational Site Corvallis, Oregon, United States United States, Tennessee 1200.167.01002 Boehringer Ingelheim Investigational Site Chattanooga, Tennessee, United States 1200.167.01006 Boehringer Ingelheim Investigational Site Chattanooga, Tennessee, United States 1200.167.01005 Boehringer Ingelheim Investigational Site Nashville, Tennessee, United States United States, Virginia 1200.167.01003 Boehringer Ingelheim Investigational Site Richmond, Virginia, United States Less <<
NCT01999985 Lung Cancer N... More >>on-small Cell Lung Cancer (NSCLC) Less << Phase 1 Active, not recruiting March 2019 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Less <<
NCT01531764 Carcinoma Breast Stage IV Phase 2 Terminated(The recruitment was... More >> discontinued because of failure to meet expected enrolment goals) Less << - Germany ... More >> Klinikum St. Marien Amberg Amberg, Bayern, Germany, 92224 Hämato-Onkologische Schwerpunktpraxis München, Bayern, Germany, 80638 Caritas-Krankenhaus, Onkologisches Zentrum Regensburg Regenburg, Bayern, Germany, 93053 Gynäkologische Praxis Hildesheim, Niedersachsen, Germany, 31134 Schwerpunktpraxis für Hämatologie und Onkologie Bottrop, Nordrhein-Westfalen, Germany, 46236 Universitätsklinikum Frauenklinik Düsseldorf Düsseldorf, Nordrhein-Westfalen, Germany, 40225 Otto-von-Guericke-Universität Frauenklinik Magdeburg Magdeburg, Sachsen-Anhalt, Germany, 39108 Klinikum Chemnitz gGmbH Chemnitz, Sachsen, Germany, 09116 Praxisklinik Krebsheilkunde für Frauen / Brustzentrum Berlin, Germany, 10367 Onkologisches Zentrum Süd, Vivantes Tumorzentrum Berlin, Germany, 12351 Internistische Praxisgemeinschaft Eppendorf Hamburg, Germany, 20249 OncoResearch Lerchenfled UG Hamburg, Germany, 22081 Less <<
NCT01466660 Lung Neoplasms Phase 2 Active, not recruiting October 16, 2018 -
NCT01466660 - Active, not recruiting - -
NCT02271906 Lung Cancer Phase 2 Terminated(Poor Accrual) - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01743365 Gastric Cancer ... More >> Gastroesophageal Junction Cancer Less << Phase 2 Active, not recruiting June 2019 Greece ... More >> 2nd Dept of Internal Medicine, Agios Savvas Cancer Hospital Athens, Greece, 11522 Dept of Medical Oncology, 251 Air Force Hospital Athens, Greece, 11525 2nd Dept of Internal Medicine, General Hospital of Athens "Hippokratio" Athens, Greece, 11527 Oncology Section, Dept of Clinical Therapeutics, General Hospital of Athens "Alexandra" Athens, Greece, 11528 Division of Oncology, 2nd Dept of Internal Medicine, University Hospital "Attikon" Athens, Greece, 12462 2nd Dept of Medical Oncology, Agii Anargiri Cancer Hospital Athens, Greece, 14564 3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital Athens, Greece, 14564 3rd Dept of Medical Oncology, Hygeia Hospital Athens, Greece, 15123 1st Dept of Medical Oncology, Metropolitan Hospital Athens, Greece, 18547 2nd Dept of Medical Oncology, Metropolitan Hospital Athens, Greece, 18547 Dept of Medical Oncology, University Hospital of Heraklion Heraklion, Greece, 71110 Dept of Medical Oncology, Ioannina University Hospital Ioannina, Greece, 45110 Division of Oncology, Dept of Internal Medicine, University Hospital of Patras Patras, Greece, 26504 Dept of Medical Oncology, Papageorgiou General Hospital Thessaloniki, Greece, 56429 Dept of Medical Oncology, Thermi Clinic S.A Thessaloniki, Greece, 57001 Less <<
NCT01783587 Squamous Cell Carcinoma of the... More >> Head and Neck Less << Phase 1 Active, not recruiting February 2019 United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New York Mount Sinai Medical Center/Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Less <<
NCT01415011 Carcinoma, Non-Small-Cell Lung Phase 2 Active, not recruiting September 2018 United Kingdom ... More >> Royal Bournemouth Hospital Bournemouth, United Kingdom Beatson West of Scotland Cancer Centre Glasgow, United Kingdom James Paget University Hospital Great Yarmouth, United Kingdom East Kent Hospitals Kent, United Kingdom Maidstone Hospital Kent, United Kingdom St James's University Hospital Leeds, United Kingdom The Royal Marsden Hospitals London Borough of Sutton, United Kingdom Barnet & Chase Farm Hospitals London, United Kingdom Charing Cross Hospital London, United Kingdom Guy's Hospital London, United Kingdom University College Hospital London, United Kingdom Musgrove Park Hospital Somerset, United Kingdom King's Mill Hospital Sutton in Ashfield, United Kingdom Weston General Hospital Weston Super Mare, United Kingdom York Hospital York, United Kingdom Less <<
NCT01853826 Carcinoma, Non-Small-Cell Lung Phase 3 Active, not recruiting March 31, 2019 -
NCT01542437 Non-Small Cell Lung Cancer ... More >> EGFR HER-2 Less << Phase 2 Active, not recruiting June 2017 Mexico ... More >> National Cancer Institute of Mexico Mexico city, Distrito Federal, Mexico, 14080 Less <<
NCT03727724 Carcinoma, Non-Small-Cell Lung Phase 2 Active, not recruiting May 2021 Netherlands ... More >> Antoni van Leeuwenhoek Amsterdam, North-Holland, Netherlands, 1066 CX VU Medical Center Amsterdam, Netherlands, 1007 MB University Medical Center Groningen Groningen, Netherlands, 9713 GZ Maastricht UMC+ Maastricht, Netherlands, 6229 HX Less <<
NCT02044380 Carcinoma, Non-Small-Cell Lung Phase 3 Completed - Canada, Ontario ... More >> Boehringer Ingelheim Investigational Site Barrie, Ontario, Canada Boehringer Ingelheim Investigational Site London, Ontario, Canada Boehringer Ingelheim Investigational Site Newmarket, Ontario, Canada Boehringer Ingelheim Investigational Site Toronto, Ontario, Canada Canada, Quebec Boehringer Ingelheim Investigational Site Montreal, Quebec, Canada Less <<
NCT01538381 Carcinoma, Squamous Cell of He... More >>ad and Neck Less << Phase 2 Completed - Belgium ... More >> Institut Jules Bordet Brussels, Belgium, 1000 Cliniques Universitaires St. Luc Brussels, Belgium, 1200 U.Z. Leuven - Campus Gasthuisberg Leuven, Belgium, 3000 Italy Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Milano, Italy, 20133 Less <<
NCT01320280 Refractory Cancer Phase 2 Completed - Germany ... More >> University Medical Center Hamburg-Eppendorf Hamburg, Germany, 20246 Less <<
NCT01746251 Non Small Cell Lung Cancer Phase 2 Active, not recruiting August 2019 United States, California ... More >> Stanford University Palo Alto, California, United States, 94304 United States, Massachusetts Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Massachusetts General Hospital Boston, Massachusetts, United States, 02115 United States, New York Memorial Sloan Kettering New York, New York, United States, 10065 Less <<
NCT02747953 Non-small Cell Lung Cancer Phase 2 Completed - -
NCT02208843 Carcinoma, Non-Small-Cell Lung Phase 4 Completed - Egypt ... More >> 1200.217.2201 Boehringer Ingelheim Investigational Site Alexandria, Egypt 1200.217.2202 Boehringer Ingelheim Investigational Site Cairo, Egypt 1200.217.2203 Boehringer Ingelheim Investigational Site Cairo, Egypt Malaysia 1200.217.6001 Boehringer Ingelheim Investigational Site Nilai, Malaysia Philippines 1200.217.6301 Boehringer Ingelheim Investigational Site Baguio City, Philippines 1200.217.6303 Boehringer Ingelheim Investigational Site Taguig, Philippines Poland 1200.217.4803 Boehringer Ingelheim Investigational Site Gdansk, Poland 1200.217.4805 Boehringer Ingelheim Investigational Site Szczecin-Zdunowo, Poland 1200.217.4801 Boehringer Ingelheim Investigational Site Warsaw, Poland Romania 1200.217.4004 Boehringer Ingelheim Investigational Site Braila, Romania 1200.217.4002 Boehringer Ingelheim Investigational Site Bucharest, Romania 1200.217.4005 Boehringer Ingelheim Investigational Site Craiova, Romania 1200.217.4003 Boehringer Ingelheim Investigational Site Iasi, Romania Serbia 1200.217.3801 Boehringer Ingelheim Investigational Site Belgrade, Serbia 1200.217.3802 Boehringer Ingelheim Investigational Site Belgrade, Serbia 1200.217.3804 Boehringer Ingelheim Investigational Site Kragujevac, Serbia 1200.217.3803 Boehringer Ingelheim Investigational Site Sremska Kamenica, Serbia Thailand 1200.217.6601 Boehringer Ingelheim Investigational Site Bangkok, Thailand 1200.217.6603 Boehringer Ingelheim Investigational Site Bangkok, Thailand 1200.217.6604 Boehringer Ingelheim Investigational Site Bangkok, Thailand 1200.217.6602 Boehringer Ingelheim Investigational Site Songkhla, Thailand Less <<
NCT02044380 - Completed - -
NCT02096718 - Completed - -
NCT02096718 Renal Insufficiency Phase 1 Completed - Germany ... More >> 1200.216.1 Boehringer Ingelheim Investigational Site Kiel, Germany Less <<
NCT01814553 - Completed - -
NCT01824823 Head and Neck Squamous Cell Ca... More >>rcinoma Less << Phase 2 Active, not recruiting December 2020 -
NCT01824823 - Active, not recruiting - -
NCT02629523 Lung Neoplasms ... More >> EGFR Gene Mutation Less << Phase 2 Active, not recruiting March 2019 Korea, Republic of ... More >> Chonnam National University Hwasun Hospital Hwasun, Jeonnam, Korea, Republic of, 58128 Less <<
NCT01953913 Carcinoma, Non-Small-Cell Lung Phase 3 Completed - China ... More >> 307 Hospital of PLA Beijing, China, 100071 Beijing Cancer Hospital Beijing, China, 100142 Chinese PLA General Hospital Beijing, China, 100853 Jilin Province Cancer Hospital Changchun, China Guangdong General Hospital Guangzhou, China, 510080 Zhejiang Cancer Hospital Hangzhou, China, 310022 Lin Yi Tumor Hospital Linyi, China, 276002 Jiangsu Cancer Hospital Nanjing, China, 210000 Shanghai Chest Hospital Shanghai, China, 200030 Fudan University Shanghai Cancer Center Shanghai, China, 200032 Shanghai Pulmonary Hospital Shanghai, China, 200433 Tianjin Medical University Cancer Institute and Hospital Tianjin, China, 300060 Hong Kong Queen Mary Hospital Hong Kong, Hong Kong Prince of Wales Hospital Shatin, Hong Kong India Vikram Hospital Bangalore, India, 560052 HCG Hospital Bengaluru, India, 560027 P VS Hospital Pvt Ltd Calicut, India, 673002 V S Hospital Chennai, India, 600031 Max Super Speciality Hospital, Delhi Delhi, India, 110092 Global Hospitals Hyderabad, India, 500004 Basavatarakam Indo - American Cancer Hospital & Research Ins Hyderabad, India, 500034 SEAROC Cancer Centre Jaipur, India, 302004 B. P. Poddar Hospital & Medial Research Ltd Kolkata,West Bengal, India, 700053 Asirvatham Multispeciality Hospital Madurai, India, 625 020 Curie Manavata Cancer Centre Maharashtra, India, 422 004 Shatabdi Superspeciality Hospital Maharashtra, India, 422005 Prince Aly Khan Hospital Mumbai, India, 400010 Ruby Hall Clinic Pune, India, 411001 Singapore National Cancer Centre Singapore, Singapore, 169610 Taiwan E-Da Hospital Kaohsiung, Taiwan, 824 NCKUH Tainan, Taiwan, 704 Tri-Service General Hospital Taipei, Taiwan, 11490 Chang-Gung Memorial Hospital, Linkou Taoyuan County, Taiwan, 333 Less <<
NCT02501603 Gastric Cancer ... More >> Gastroesophageal Junction Cancer Less << Phase 2 Recruiting December 2018 Korea, Republic of ... More >> Severance Hospital, Yonsei University Health System, Yonsei Cancer Center Recruiting Seoul, Korea, Republic of, 120-752 Contact: Hyosong Kim, M.D    82-2-2228-8124    hyosong77@yuhs.ac Less <<
NCT02122172 Distal Urethral Cancer ... More >> Proximal Urethral Cancer Recurrent Bladder Cancer Recurrent Urethral Cancer Stage III Bladder Cancer Stage III Urethral Cancer Stage IV Bladder Cancer Stage IV Urethral Cancer Ureter Cancer Less << Phase 2 Recruiting June 12, 2019 United States, Illinois ... More >> University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Peter H. O'Donnell    773-702-7564    podonnel@medicine.bsd.uchicago.edu    Principal Investigator: Peter H. O'Donnell          Decatur Memorial Hospital Recruiting Decatur, Illinois, United States, 62526 Contact: James L. Wade    217-876-6600    JLWADE3@sbcglobal.net    Principal Investigator: James L. Wade          NorthShore University Health System Completed Evanston, Illinois, United States, 60201 Less <<
NCT02491099 HER2/Neu+ Uterine Serous Carci... More >>noma Less << Phase 2 Recruiting June 2021 United States, Arizona ... More >> University of Arizona Cancer Center Recruiting Tucson, Arizona, United States, 85724 Contact: Setsuko Chambers, M.D.    520-626-0950    schambers@uacc.arizona.edu    Contact: Elizabeth Collins, BSHCA    520-694-9067    jenniecollins@email.arizona.edu    United States, Connecticut Yale New Haven Hospital Recruiting New Haven, Connecticut, United States, 06510 Contact: Alessandro D. Santin, M.D.    203-737-4450    alessandro.santin@yale.edu    Contact: Lisa Baker, R.N.    203-785-6398    lisa.baker@yale.edu    United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Whitfield Growdon, MD    617-724-4800    wgrowdon@partners.org    Contact: Louisa Bauer, RN    617-643-5415    LJBAUER@mgh.harvard.edu    Principal Investigator: Whitfield Growdon, MD Less <<
NCT02274012 HER-2 Positive Gastric Cancer ... More >> Gastrooesophageal Cancer Esophageal Cancer Less << Phase 2 Withdrawn(Former PI left insti... More >>tution and had plans to continue at another institution.) Less << - -
NCT01522768 Esophageal Cancer ... More >> Gastric Cancer Less << Phase 2 Recruiting February 2019 United States, California ... More >> University of Southern California Recruiting Los Angeles, California, United States, 90033 Contact: Syma Iqbal, MD    323-865-3907       Principal Investigator: Syma Iqbal, MD          United States, Massachusetts Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Janet Murphy, MD    617-724-5600       United States, New Jersey Memoral Sloan Kettering Basking Ridge Recruiting Basking Ridge, New Jersey, United States Contact: Yelena Janjigian, MD          Principal Investigator: Yelena Janjigian, MD          Memoral Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Yelena Janjigian, MD    646-888-4186       Memorial Sloan Kettering Bergen Recruiting Montvale, New Jersey, United States, 07645 Contact: Yelena Janjigian, MD    646-888-4186       United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Yelena Janjigian, MD          Principal Investigator: Yelena Janjigian, MD          Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Yelena Janjigian, MD    646-888-4186       Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Yelena Janjigian, MD    646-888-4186       Contact: David Ilson, MD    646-888-4183       Principal Investigator: Yelena Janjigian, MD          Memorial Sloan Kettering Rockville Centre Recruiting Rockville Centre, New York, United States Contact: Yelena Janjigian, MD          Principal Investigator: Yelena Janjigian, MD Less <<
NCT02369484 NSCLC Phase 2 Completed - Germany ... More >> Universitätsklinikum Köln Köln, Germany Netherlands NKI-AVL Amsterdam, Netherlands Spain Vall d'Hebron University Hospital Barcelona, Spain Switzerland CHUV Lausanne, Switzerland USZ Zürich, Switzerland Less <<
NCT02364609 Recurrent Non-Small Cell Lung ... More >>Carcinoma Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IV Non-Small Cell Lung Cancer Less << Phase 1 Active, not recruiting December 2018 United States, California ... More >> University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 Less <<
NCT02695290 - Terminated - -
NCT02514174 Carcinoma, Non-Small-Cell Lung... More >> ErbB Receptors Less << Phase 4 Active, not recruiting December 18, 2018 United States, Arizona ... More >> Mayo Clinic-Phoenix Scottsdale, Arizona, United States, 85250 United States, California Pacific Cancer Medical Center, Inc. Anaheim, California, United States, 92801 City of Hope Duarte, California, United States, 91010 Compassionate Care Research Group, Inc. at Compassionate Cancer Care Medical Group, Inc. Fountain Valley, California, United States, 92708 Los Angeles Hematology Oncology Medical Group Los Angeles, California, United States, 90017 United States, Florida University of Miami Miami, Florida, United States, 33136 United States, Illinois Ingalls Memorial Hospital Harvey, Illinois, United States, 60426 United States, Massachusetts Baystate Health D'Amour Center for Cancer Care Springfield, Massachusetts, United States, 01199 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467 United States, Pennsylvania Lankenau Medical Center Wynnewood, Pennsylvania, United States, 19096 Less <<
NCT02695290 Carcinoma, Non-Small-Cell Lung... More >> ErbB Receptors Less << Phase 4 Terminated - United States, California ... More >> 1200.208.10032 Boehringer Ingelheim Investigational Site Fountain Valley, California, United States Less <<
NCT03711422 Non-small Cell Lung Cancer ... More >> Leptomeningeal Disease Central Nervous System Metastases Less << Phase 1 Not yet recruiting September 30, 2020 -
NCT01427478 Head and Neck Squamous Cell Ca... More >>rcinoma Less << Phase 3 Active, not recruiting September 2021 France ... More >> Centre Paul Papin Angers, France, 49933 Institut Sainte-Catherine Avignon, France, 84000 CHU Bordeaux - Hôpital Saint-André Bordeaux, France, 33075 Polyclinique de Bordeaux Nord Bordeaux, France, 33300 CHRU Brest - Hôpital Morvan Brest, France, 29609 Centre François Baclesse Caen, France, 14076 CHIC Créteil Créteil, France, 94010 Centre Guillaume le Conquérant Le Havre, France, 76600 Centre Hospitalier Bretagne Sud Lorient, France, 56100 Centre Léon Bérard Lyon, France, 69373 AP-HM La Timone Adultes Marseille, France, 13386 Cedex Centre Antoine Lacassagne Nice, France, 06189 CHU Poitiers Poitiers, France, 86021 Centre Eugène Marquis Rennes, France, 44229 Centre Henri Becquerel Rouen, France, 76038 Institut de Cancérologie de la Loire Saint Priest en Jarez, France, 42270 Institut de Cancérologie de l'Ouest Saint-Herblain, France, 44805 Pôle Hospitalier Mutualiste- Centre Etienne Dolet Saint-Nazaire, France, 44600 Strasbourg Oncologie Libérale Strasbourg, France, 67000 Hopitaux du Léman Thonon-les-bains, France, 74203 Clinique Pasteur Bâtiment l'Atrium Toulouse, France, 31076 Institut Claudius Regaud Toulouse, France, 71000 CHU TOURS (Hôpital Bretonneau) Tours, France, 37044 Centre de Radiothérapie Marie Curie Valence, France, 26000 Institut de Cancérologie de lorraine (ICL) Vandoeuvre-les-Nancy, France, 54519 cedex Institut Gustave Roussy Villejuif, France, 94805 Less <<
NCT01415674 Carcinoma, Squamous Cell of He... More >>ad and Neck Less << Phase 2 Completed - France ... More >> CHU d'Angers Angers, France Institut de cancérologie de l'Ouest - Site Paul Papin Angers, France Centre François Baclesse Caen, France, 14000 Centre Léon Bérard Lyon, France, 69373 Institut de cancérologie de l'Ouest - Site René Gauducheau Nantes Saint-herblain, France Chu de Nantes Nantes, France Centre Antoine Lacassagne Nice, France, 06189 Institut Curie Paris, France, 75248 Institut Claudius Regaud Toulouse, France, 31052 Centre Alexis Vautrin Vandoeuvre les Nancy, France, 54511 Institut Gustave Roussy Villejuif, France, 94800 Less <<
NCT02511847 Triple Negative Breast Cancer Phase 2 Unknown July 2017 Taiwan ... More >> National Taiwan University Hospital Recruiting Taipei City, Taiwan, 110 Contact: Chiun-Sheng Huang    886-23123456 ext 65080 Less <<
NCT02625168 Lung Cancer Phase 2 Completed - Hong Kong ... More >> Department of Clinical Oncology, Queen Mary Hospital Hong Kong, Hong Kong Less <<
NCT03486509 Squamous Cell Carcinoma Phase 2 Not yet recruiting July 1, 2020 -
NCT02423525 Brain Cancer Phase 1 Recruiting December 2020 United States, California ... More >> John Wayne Cancer Institute Recruiting Santa Monica, California, United States, 90404 Contact: Jaya Gill, RN    310-582-7437    jaya.gill@providence.org    Principal Investigator: Santosh Kesari, MD, PhD Less <<
NCT03083678 Chordoma Phase 2 Recruiting December 2019 Italy ... More >> Istituto Nazionale dei Tumori: Fondazione IRCCS Not yet recruiting Milan, Italy Contact: S Stacchiotti, MD          Netherlands Leiden University Medical Center Recruiting Leiden, Netherlands Contact: H Gelderblom, MD Prof          United Kingdom University College London Hospital Not yet recruiting London, United Kingdom Contact: S Strauss, MD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.06mL

0.41mL

0.21mL

10.29mL

2.06mL

1.03mL

20.58mL

4.12mL

2.06mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories